Find out more soon about our expertise as an innovative company and our objective of addressing important unmet medical needs in the areas of innate immunity, inflammation and organ/function repair.
| Date | Notification | Press release |
| 04 October 2022 | S.F.P.I/F.P.I.M | EN - FR |
| 16 March 2022 | Nyenburgh Holding BV | EN - FR |
| 14 December 2021 | S.R.I.W SA & Sofipôle | EN - FR |
| 8 December 2021 | Nyenburgh Holding BV | EN - FR |
| 22 December 2020 | CPH Banque | EN - FR |
| 16 October 2020 | S.R.I.W SA & Sofipôle | EN - FR |
| 26 May 2020 | S.R.I.W SA & Sofipôle | EN - FR |
| 3 December 2019 | S.R.I.W. SA & Sofipôle | EN - FR |
| 11 July 2019 | S.R.I.W. SA & Sofipôle | EN - FR |
| 2 July 2019 | Mr J. Reymann | EN - FR |
| 4 December 2018 | S.R.I.W. SA & Sofipôle | EN - FR |
| 29 March 2018 | S.R.I.W. SA & Sofipôle | EN - FR |
| 11 October 2016 | Theodorus II SA | EN - FR - NL |
| 22 October 2015 | S.R.I.W. SA & Sofipôle | EN - FR - NL |
| 17 February 2015 | S.R.I.W. SA & Sofipôle | EN - FR - NL |
| 17 February 2015 | Mr J. Reymann | EN - FR - NL |
| 17 February 2015 | SFPI SA | EN - FR - NL |
| 17 February 2015 | Theodorus II SA | EN - FR - NL |